Spartalizumab |
PDR-001 |
Phase Ⅲ |
Novartis |
Melanoma |
Details
|
INSIX RA (Indus Biotech) |
|
Phase Not Specified |
Indus Biotech Private Limited |
Inflammation, Rheumatoid arthritis (RA) |
Details
|
Pidilizumab |
CT-011; MDV-9300 |
Phase Ⅱ |
|
Glioma, Diffuse large B cell lymphoma, Prostate cancer, Follicular lymphoma, Multiple myeloma (MM), Colorectal cancer, Acute myeloid Leukemia (AML), Hepatocellular carcinoma (HCC), Renal carcinoma, HCV infection, Pancreatic cancer, Melanoma |
Details
|
CS-1003 |
CS-1003 |
Phase Ⅲ |
CStone Pharmaceuticals |
Hepatocellular carcinoma (HCC) |
Details
|
BI-754091 |
BI-754091 |
Phase Ⅱ |
Boehringer Ingelheim |
Solid tumours |
Details
|
Cetrelimab |
JNJ-63723283; JNJ-3283 |
Phase Ⅲ |
Johnson & Johnson |
Multiple myeloma (MM) |
Details
|
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) |
|
Phase Ⅰ |
Marino Biotechnology, Chengdu Galaxy Biomed, Peking University |
B-cell lymphoma |
Details
|
AK-104 |
AK-104,AK104 |
Phase Ⅱ |
Akeso Biopharma |
Solid tumours |
Details
|
PD-1 knockout EBV-CTL (Nanjing Medical University) |
|
Phase Ⅱ |
Nanjing Medical University |
Nasopharyngeal cancer, Gastric cancer, Diffuse large B cell lymphoma, Lymphoma, Hodgkin lymphoma |
Details
|
Genolimzumab |
CBT-501; GB-226 |
Phase Ⅱ |
Genor Biopharma, CBT |
Thymic tumor, Solid tumours, Soft tissue sarcoma, Hepatocellular carcinoma (HCC), Peripheral T cell lymphoma (PTCL), Non-Hodgkin B-cell lymphomas, Cervical carcinoma |
Details
|
AK-112 |
AK-112,AK112 |
Phase Ⅰ |
Akeso Biopharma |
Malignancies |
Details
|
TY-101 |
TY-101,TY101 |
Phase Ⅱ |
大有生物 |
Solid tumours, Lymphoma |
Details
|
MAX-10181 |
MAX-10181 |
Phase Ⅰ |
Maxinovel Pharmaceuticals |
Solid tumours |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
Multiple myeloma (MM) |
Details
|
GS-4224 |
GS-4224 |
Phase Ⅱ |
Gilead Sciences |
Solid tumours |
Details
|
609-A (SBio) |
609-A |
Phase Ⅰ |
3SBio |
Solid tumours |
Details
|
CA-170 |
CA-170; AUPM-170 |
Phase Ⅱ |
Aurigene, Curis |
Cancer |
Details
|
Nivolumab/Relatlimab |
BMS-936558/BMS-986016; BMS-986213 |
Phase Ⅲ |
Bristol-Myers Squibb |
Melanoma |
Details
|
REMD-288 |
REMD-288 |
Preclinical |
REMD Biotherapeutics, Buchang Pharma |
Cancer |
Details
|
LY-3434172 |
LY-3434172 |
Phase Ⅰ |
Lilly |
Solid tumours |
Details
|
INCB-086550 |
INCB-086550 |
Phase Ⅰ |
Incyte |
Solid tumours |
Details
|
Dostarlimab |
ANB-011; TSR-042; WBP-285 |
BLA Filing |
AnaptysBio, Tesaro, GlaxoSmithKline |
Fallopian tube cancer, Endometrial cancer, Peritoneum cancer, Ovarian cancer |
Details
|
AK-105 |
AK-105,AK105; AK 105 |
BLA Filing |
Akeso Biopharma |
Metastatic non-small cell lung cancer, Nasopharyngitis, Solid tumours, Hepatocellular carcinoma (HCC), Hodgkin lymphoma |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody(Akeso Biopharma) |
AK-103; HX-008 |
Phase Ⅲ |
Akeso Biopharma, Taizhou Hanzhong Biomed, Hansi Biological Pharmaceutical |
Gastroesophageal junction adenocarcinoma |
Details
|
MiHA-loaded PD-L silenced DC vaccination (Radboud University) |
|
Phase Ⅱ |
Radboud University |
Multiple myeloma (MM), Acute myeloid Leukemia (AML), Non-Hodgkin's lymphoma (NHL), Chronic myeloid leukemia (CML ) |
Details
|
AMP-224 |
AMP-224; AMP-244; GSK-2661380 |
Phase Ⅰ |
Amplimmune, MedImmune, National Cancer Institute, GlaxoSmithKline |
Solid tumours, Colorectal cancer |
Details
|
Balstilimab |
AGEN2034; RebmAb-700 |
Phase Ⅱ |
Agenus, Ludwig Institute for Cancer Research |
Solid tumours, Cervical carcinoma |
Details
|
RG-6084 |
RG-6084 |
Phase Ⅰ |
Roche |
HBV infection |
Details
|
Retifanlimab |
INCMGA-0012; INCMGA-00012; MGA-012 |
Phase Ⅲ |
MacroGenics, Incyte, Zai Lab |
Gastric cancer, oesophageal cancer |
Details
|
BCD-217 |
BCD-217 |
Phase Ⅱ |
Biocad |
Melanoma |
Details
|
SL-279252 |
SL-279252; TAK-252 |
Phase Ⅰ |
Shattuck Labs |
Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Renal cell carcinoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hodgkin lymphoma, Gastroesophageal junction adenocarcinoma, Melanoma |
Details
|
T3011疱疹病毒(深圳市亦诺微医药) |
|
Phase Ⅰ |
|
Solid tumours |
Details
|
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
B-cell lymphoma |
Details
|
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) |
SG-001 |
Phase Ⅰ |
Hangzhou sumgen biotechnology |
Solid tumours |
Details
|
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) |
|
Phase Ⅱ |
HengRui YuanZheng Biotechnology |
Solid tumours |
Details
|
MEDI-0680 |
AMP-514; MEDI-0680,AMP514; MEDI0680 |
Phase Ⅱ |
MedImmune |
B-cell lymphoma |
Details
|
Sym-021 |
Sym-021,Sym 021; Sym021 |
Phase Ⅰ |
Symphogen |
Solid tumours, Lymphoma |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical) |
|
Phase Ⅰ |
Shandong Xinshidai Pharmaceutical |
Solid tumours |
Details
|
Programmed cell death 1 antibody (Sun Yat-sen University) |
|
Phase Ⅱ |
Sun Yat-sen University |
Hepatocellular carcinoma (HCC) |
Details
|
STW204单抗 |
STW-204 |
Phase Ⅰ |
Stainwei |
Solid tumours |
Details
|
Millamolecule |
|
Phase Ⅰ |
Bristol-Myers Squibb |
Immunological disorders |
Details
|
RO-7121661 |
RG-7769; RO-7121661 |
Phase Ⅱ |
Roche |
Non small cell lung cancer (NSCLC), Solid tumours, Melanoma |
Details
|
XmAb20717 |
XmAb-20717,XmAb 20717 |
Phase Ⅰ |
Xencor |
Solid tumours |
Details
|
CC-90006 |
C-90006; CC-90006 |
Phase Ⅰ |
AnaptysBio, Celgene |
Autoimmune diseases, Psoriasis |
Details
|
YBL-006 |
YBL-006 |
Phase Ⅰ |
Y Biologics |
Advanced solid tumors |
Details
|
ONO-4685 |
ONO-4685 |
Phase Ⅰ |
Merus, Ono Pharmaceutical |
Autoimmune diseases |
Details
|
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) |
|
Phase Ⅱ |
Chongqing Xinqiao Hospital |
Squamous cell carcinoma of head and neck cancer (SCCHN) |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) |
BAT-1306,BAT1306 |
Phase Ⅱ |
Bio-Thera Solutions |
Gastric cancer, Colorectal neoplasms, Solid tumours, Liver cancer |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) |
|
Phase Ⅰ |
Anke Biotechnology |
Triple negative breast cancer, Esophagus cancer, Urothelial cancer, Lung cancer, Lymphoma |
Details
|
HLX-10 |
HLX-10 |
Phase Ⅲ |
Shanghai Henlius Biotech |
Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), oesophageal cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Liver cancer |
Details
|
MGD-019 (MacroGenics) |
MGD-019 |
Phase Ⅰ |
MacroGenics |
Solid tumours |
Details
|
IBI318 |
IBI-318 |
Phase Ⅰ |
Innovent Biologics, Lilly |
hematological malignancies, Malignancies |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech) |
SCT-I10A |
Phase Ⅲ |
Sinocelltech |
Squamous cell carcinoma of head and neck cancer (SCCHN) |
Details
|
Sasanlimab |
PF-06801591; PF-6801591; RN-888 |
Phase Ⅲ |
Pfizer |
Bladder cancer |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase Ⅱ |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
CS-17938 |
CS17938 |
Preclinical |
ChipScreen |
Immunological disorders, Cancer |
Details
|
IBI315 |
IBI-315; IBI315 |
Phase Ⅰ |
Innovent Biologics, Hanmi |
Cancer |
Details
|
RB-0004 |
RB-0004,RB0004; RB 0004 |
Phase Ⅰ |
Reyoung Pharmaceutical |
Malignancies |
Details
|
Recombinant human anti-PD-1 monoclonal antibody(Yiyi Health Technology) |
|
Phase Ⅰ |
Yiyi Health Technology |
Malignancies |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) |
|
Phase Ⅰ |
Shanghai CP Guojian |
Solid tumours |
Details
|
JTX-4014 (Jounce Therapeutics) |
JTX-4014 |
Phase Ⅰ |
Jounce Therapeutics |
Cancer |
Details
|
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) |
|
Phase Ⅱ |
Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital |
Esophagus cancer |
Details
|
IMU-201 |
IMU-201,PD1-Vaxx |
Phase Ⅰ |
Imugene |
Non small cell lung cancer (NSCLC) |
Details
|
CMAB-819 |
CMAB8-19,CMAB819; CMAB8 19 |
Phase Ⅰ |
SinoMab Bioscience Ltd, Taizhou Mabtech |
Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC) |
Details
|
CX-188 |
|
IND Filing |
CytomX Therapeutics |
Cancer |
Details
|
PD-1 knockout engineered T cells (Cell Biotech) |
|
Phase Ⅰ |
Cell Biotech |
Renal cell carcinoma, Prostate cancer, Bladder cancer |
Details
|
PD-1 knockout engineered T cells (Chengdu MedGenCell) |
|
Phase Ⅱ |
Chengdu MedGenCell, West China Hospital Sichuan University |
Lung cancer, Melanoma |
Details
|
Zimberelimab |
AB-122; GLS-010; WBP-3055 |
BLA Filing |
Gloria Pharmaceuticals, WuXi AppTec, Arcus Biosciences |
Triple negative breast cancer, Gastric cancer, Solid tumours, Liver cancer, Hodgkin lymphoma |
Details
|
MEDI-5752 |
MEDI-5752 |
Phase Ⅰ |
MedImmune |
Solid tumours |
Details
|
MGD-013 |
MGD-013; PD-1 X LAG-3 |
Phase Ⅲ |
MacroGenics, Zai Lab |
Gastric cancer, oesophageal cancer |
Details
|
Recombinant human PD-1 antibody herpes simplex virus |
|
Phase Ⅰ |
Yangshengtang Co, Xiamen University |
Cancer |
Details
|
HX-009 |
HX-009,HX009 |
Phase Ⅰ |
Hansi Biological Pharmaceutical, Wuhan Hanxiong Biotechnology Co., Ltd. |
Gastric cancer, Colorectal neoplasms, Liver cancer |
Details
|
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase Ⅱ |
Innovative Cellular Therapeutics |
Non-Hodgkin's lymphoma (NHL) |
Details
|
RO-7247669 |
RO-7247669 |
Phase Ⅰ |
Roche |
Solid tumours |
Details
|
Budigalimab |
ABBV-181 |
Phase Ⅰ |
Abbvie |
Non small cell lung cancer (NSCLC), Solid tumours, Colorectal cancer, Ovarian cancer |
Details
|
LZM-009 |
LZM-009,LZM009 |
Phase Ⅰ |
Livzon Group Livzon Pharmaceutical Factory |
Solid tumours |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) |
|
IND Filing |
Shanxi Wichida Bright Pharmaceutical |
Unspecified |
Details
|